{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:44:03Z","timestamp":1787024643671,"version":"build-2736575974"},"reference-count":41,"publisher":"Bentham Science Publishers Ltd.","issue":"1","license":[{"start":{"date-parts":[[2022,12,22]],"date-time":"2022-12-22T00:00:00Z","timestamp":1671667200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/legalcode"}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CDS"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Temporal lobe epilepsy (TLE) has the highest probability of becoming resistant.\nOne of the causes was Polymorphism in multidrug resistant-1 (MDR1) C3435T. In Dr.\nCipto Mangunkusumo Hospital, potential drug-resistant epilepsy prevalence was 84.51%; 66.6%\nof them used carbamazepine (CBZ) as antiseizure medication. This comparative cross-sectional\nstudy aimed to investigate MDR1 C3435T polymorphism and CBZ plasma level (plCBZ) in Indonesian\nTLE patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>TLE patient was selected consecutively; divided into drug-responsive (DRV) and drugresistant\n(DRE) groups. Healthy subjects were included as a control for the gene polymorphism\ncomparison. MDR1 was identified using the restriction fragment length polymorphism PCR technique;\nC allele at 159 and 57bp while T allele at 216bp. High-performance liquid chromatography\nwas used to determine plCBZ.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>There were 86 subjects; 61 in the study group and 25 controls. The genotype distribution\nbetween them was 0.58 vs 0.42, x2=0.54, p=0.000. In the study group, CBZ within therapeutic doses\n(dCBZ) had outreached the therapeutic plCBZ and found similar in all genotypes. DRE criteria\nwere found in 37 subjects. Distribution of C and T in DRV was 0.63 vs 0.37, x2=10.4; and DRE\n0.55 vs 0.45 x2=6.17 (p=0.019). In Tukey\u2019s multiple comparison post hoc test, CT in DRV had\nsignificantly lower dCBZ (330,36 \u00b1 174,91 mg) and plCBZ (7.15 \u00b1 2.64 mcg\/mL) compared to all\ngenotypes in DRE. Whereas mean dCBZ was around 800mg and plCBZ outreached the toxic level;\nTT was the highest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>The genotype MDR1 distribution was similar in the normal population and DRE.\nTherapeutic plCBZ was achieved using the low dose. CT genotype responds to lower dCBZ, while\nTT genotype outreached the highest toxic plCBZ.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/1574886317666220414130526","type":"journal-article","created":{"date-parts":[[2022,4,18]],"date-time":"2022-04-18T04:09:31Z","timestamp":1650254971000},"page":"62-68","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Multidrug Resistance-1 C3435T Polymorphism and Carbamazepine Plasma\nLevel in Indonesian Temporal Lobe Epilepsy Patients"],"prefix":"10.2174","volume":"18","author":[{"given":"Rianto","family":"Setiabudy","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty\nof Medicine, Universitas Indonesia, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5244-6296","authenticated-orcid":true,"given":"Astri","family":"Budikayanti","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Universitas Indonesia\/Dr. Cipto Mangunkusumo National Referral\nGeneral Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2766-3635","authenticated-orcid":true,"given":"Herlyani","family":"Khosama","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine University of Sam Ratulangi\/\nProf. RD Kandou General Hospital, Manado, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fitri","family":"Octaviana","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Universitas Indonesia\/Dr. Cipto Mangunkusumo National Referral\nGeneral Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0391-185X","authenticated-orcid":true,"given":"Donny H.","family":"Hamid","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Universitas\nIndonesia\/Pasar Rebo Regional General Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-0380","authenticated-orcid":true,"given":"Melva","family":"Louisa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacology, Faculty\nof Medicine, Universitas Indonesia, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teguh A.S.","family":"Ranakusuma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Faculty of Medicine, Universitas Indonesia\/Dr. Cipto Mangunkusumo National Referral\nGeneral Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","volume":"51","author":"Kwan P.","year":"2010","unstructured":"Kwan P.; Arzimanoglou A.; Berg A.T.; Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010,51(6),1069-1077","journal-title":"Epilepsia"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1056\/NEJMra1004418","volume":"365","author":"Kwan P.","year":"2011","unstructured":"Kwan P.; Schachter S.C.; Brodie M.J.; Drug-resistant epilepsy. N Engl J Med 2011,365(10),919-926","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S1734-1140(12)70900-3","volume":"64","year":"2012","unstructured":"St\u0119pie\u0144 KM, Tomaszewski M, Tomaszewska J, Czuczwar SJ. The multidrug transporter P-glycoprotein in pharmacoresistance to antiepileptic drugs. Pharmacol Rep 2012,64(5),1011-1019","journal-title":"Pharmacol Rep"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.addr.2011.12.003","volume":"64","author":"Zhang C.","year":"2012","unstructured":"Zhang C.; Kwan P.; Zuo Z.; Baum L.; The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev 2012,64(10),930-942","journal-title":"Adv Drug Deliv Rev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1528-1167.2006.00504.x","volume":"47","author":"Rambeck B.","year":"2006","unstructured":"Rambeck B.; J&#xFC;rgens U.H.; May T.W.; Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Epilepsia 2006,47(4),681-694","journal-title":"Epilepsia"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1136\/jnnp.2004.045690","volume":"75","author":"Kwan P.","year":"2004","unstructured":"Kwan P.; Sander J.W.; The natural history of epilepsy: An epidemiological view. J Neurol Neurosurg Psychiatry 2004,75(10),1376-1381","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"ref=7","author":"Mardjono M.","year":"1963","unstructured":"Mardjono M.; Epilepsy: Few aspects in clinical problems with special interest in temporal lobe epilepsy. [dissertation] Jakarta: FKUI 1963"},{"key":"ref=8","author":"Gunawan P.","unstructured":""},{"key":"ref=9","first-page":"36","volume":"29","author":"Wiratman W.","year":"2012","unstructured":"Wiratman W.; Octaviana F.; Budikayanti A.; Efficacy of temporal lobe epilepsy in Cipto Mangunkusumo Hospital in Juni 2010 to Mei 2011. Neurona 2012,29(3),36-38","journal-title":"Neurona"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1056\/NEJMoa021986","volume":"348","author":"Siddiqui A.","year":"2003","unstructured":"Siddiqui A.; Kerb R.; Weale M.E.; Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N Engl J Med 2003,348(15),1442-1448","journal-title":"N Engl J Med"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0036985","volume":"7","author":"Ban J-J.","year":"2012","unstructured":"Ban J-J.; Jung K-H.; Chu K.; Profiles of multidrug resistance protein-1 in the peripheral blood mononuclear cells of patient with refractory epilepsy. PLoS One 2012,7(5),1-6","journal-title":"PLoS One"},{"key":"ref=12","first-page":"191","volume":"8","author":"Sterjev Z.","year":"2012","unstructured":"Sterjev Z.; Trencevska G.K.; Cvetkovska E.; The association of C3435T single-nucleotide polymorphism, Pgp-glycoprotein gene expression levels and carbamazepine maintenance dose in patients with epilepsy. Neuropsychiatr Dis Treat 2012,8,191-196","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1053\/seiz.2002.0593","volume":"11","author":"Kwan P.","year":"2002","unstructured":"Kwan P.; Brodie M.J.; Refractory epilepsy: A progressive, intractable but preventable condition? Seizure 2002,11(2),77-84","journal-title":"Seizure"},{"key":"ref=14","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/758407","volume":"2011","author":"Lachos J.","year":"2011","unstructured":"Lachos J.; Zattoni M.; Wieser H-G.; Characterization of the gene expression profile of human hippocampus in mesial temporal lobe epilepsy with hippocampal sclerosis. Epilepsy Res Treat 2011,2011","journal-title":"Epilepsy Res Treat"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.nbd.2010.04.006","volume":"39","author":"Kwan P.","year":"2010","unstructured":"Kwan P.; Li H.M.; Al-Jufairi E.; Association between temporal lobe P-glycoprotein expression and seizure recurrence after surgery for pharmacoresistant temporal lobe epilepsy. Neurobiol Dis 2010,39(2),192-197","journal-title":"Neurobiol Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.yebeh.2007.04.013","volume":"11","author":"Kwan P.","year":"2007","unstructured":"Kwan P.; Baum L.; Wong V.; Association between ABCB1 C3435T polymorphism and drug-resistant epilepsy in Han Chinese. Epilepsy Behav 2007,11(1),112-117","journal-title":"Epilepsy Behav"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.eplepsyres.2013.11.009","volume":"108","author":"Shaheen U.","year":"2014","unstructured":"Shaheen U.; Prasad D.K.V.; Sharma V.; Significance of MDR1 gene polymorphism C3435T in predicting drug response in epilepsy. Epilepsy Res 2014,108(2),251-256","journal-title":"Epilepsy Res"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1038\/sj.tpj.6500413","volume":"7","author":"Leschziner G.D.","year":"2007","unstructured":"Leschziner G.D.; Andrew T.; Pirmohamed M.; Johnson M.R.; ABCB1 genotype and PGP expression, function and therapeutic drug response: A critical review and recommendations for future research. Pharmacogenomics J 2007,7(3),154-179","journal-title":"Pharmacogenomics J"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0064827","volume":"8","author":"Subenthiran S.","year":"2013","unstructured":"Subenthiran S.; Abdullah N.R.; Joseph J.P.; Linkage disequilibrium between polymorphism of ABCB1 and ABCC2 to predict the treatment outcome of Malaysians with complex focal seizure on treatment with CBZ mono-therapy at the Kuala Lumpur Hospital. PLoS One 2013,8(5),1-6","journal-title":"PLoS One"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.seizure.2014.09.010","volume":"24","author":"Manna I.","year":"2015","unstructured":"Manna I.; Gambardella A.; Labate A.; Polymorphism of the multidrug resistance 1 gene MDR1\/ABCB1 C3435T and response to antiepileptic drug treatment in temporal lobe epilepsy. Seizure 2015,24,124-126","journal-title":"Seizure"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1570160043476097","volume":"2","author":"Lee C.G.","year":"2004","unstructured":"Lee C.G.; Chong S.S.; Lee E.J.D.; Pharmacogenetics of the human MDR1 multidrug transporter. Curr Pharmacogenom 2004,2,1-11","journal-title":"Curr Pharmacogenom"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/S1537-1891(02)00201-X","volume":"38","author":"Demeule M.","year":"2002","unstructured":"Demeule M.; R&#xE9;gina A.; Jodoin J.; Drug transport to the brain: Key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul Pharmacol 2002,38(6),339-348","journal-title":"Vascul Pharmacol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S0163-7258(01)00122-X","volume":"90","author":"Kwan P.","year":"2001","unstructured":"Kwan P.; Sills G.J.; Brodie M.J.; The mechanisms of action of commonly used antiepileptic drugs. Pharmacol Ther 2001,90(1),21-34","journal-title":"Pharmacol Ther"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1038\/jcbfm.2012.126","volume":"32","author":"Pardridge W.M.","year":"2012","unstructured":"Pardridge W.M.; Drug transport across the blood-brain barrier. J Cereb Blood Flow Metab 2012,32(11),1959-1972","journal-title":"J Cereb Blood Flow Metab"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/2045-8118-8-7","volume":"8","author":"Pardridge W.M.","year":"2011","unstructured":"Pardridge W.M.; Drug transport in brain via the cerebrospinal fluid. Fluids Barriers CNS 2011,8(1),7","journal-title":"Fluids Barriers CNS"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1111\/j.1528-1167.2011.03140.x","volume":"52","author":"Zhang C.","year":"2011","unstructured":"Zhang C.; Zuo Z.; Kwan P.; Baum L.; In vitro transport profile of CBZ, oxCBZ, eslicabazepine acetate, and their active metabolite by human P-glycoprotein. Epilepsia 2011,52(10),1894-1904","journal-title":"Epilepsia"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"87","DOI":"10.22159\/ijpps.2017v9i9.19402","volume":"9","author":"Budikayanti A.","year":"2017","unstructured":"Budikayanti A.; Chaliana C.; Louisa M.; Setiabudy R.; Development and validation of carbamazepine plasma concentrations measurement and its application on epilepsy patients. Int J Pharm Pharm Sci 2017,9(9),87-91","journal-title":"Int J Pharm Pharm Sci"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/j.1528-1167.2011.03121.x","volume":"52","author":"Thurman D.J.","year":"2011","unstructured":"Thurman D.J.; Beghi E.; Begley C.E.; Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia 2011,52(Suppl. 7),2-26","journal-title":"Epilepsia"},{"key":"ref=29","first-page":"117","volume":"32","author":"Aswar A.","year":"2015","unstructured":"Aswar A.; Octaviana F.; Budikayanti A.; Prihartono J.; Faktor-faktor yang memengaruhi epilepsi lobus temporal potensial resisten. Neurona 2015,32(2),117-123","journal-title":"Neurona"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.eplepsyres.2009.03.003","volume":"85","author":"Banerjee P.N.","year":"2009","unstructured":"Banerjee P.N.; Filippi D.; Allen Hauser W.; The descriptive epidemiology of epilepsy-a review. Epilepsy Res 2009,85(1),31-45","journal-title":"Epilepsy Res"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0169214","volume":"12","author":"Silva-Alves M.S.","year":"2017","unstructured":"Silva-Alves M.S.; Secolin R.; Carvalho B.S.; A prediction algorithm for drug response in patients with mesial temporal lobe epilepsy based on clinical and genetic information. PLoS One 2017,12(1)","journal-title":"PLoS One"},{"key":"ref=32","first-page":"94","volume":"12","author":"Lu Q.","year":"2007","unstructured":"Lu Q.; Wu L.; Jin L.; Xu Q.; Shen Y.; Association analysis of polymorphism of MDR1 gene and refractory temporal lobe epilepsy in a Chinese population. Neurol Asia 2007,12(Suppl. 1),94-95","journal-title":"Neurol Asia"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.eplepsyres.2007.06.003","volume":"75","author":"Hitiris N.","year":"2007","unstructured":"Hitiris N.; Mohanraj R.; Norrie J.; Sills G.J.; Brodie M.J.; Predictors of pharmacoresistant epilepsy. Epilepsy Res 2007,75(2-3),192-196","journal-title":"Epilepsy Res"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0920-1211(98)00106-5","volume":"34","author":"Regesta G.","year":"1999","unstructured":"Regesta G.; Tanganelli P.; Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res 1999,34(2-3),109-122","journal-title":"Epilepsy Res"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1212\/CON.0000000000000297","volume":"22","author":"Nair D.R.","year":"2016","unstructured":"Nair D.R.; Management of drug-resistant epilepsy. Continuum (Minneap Minn) 2016,22(1),157-172","journal-title":"Continuum (Minneap Minn)"},{"key":"ref=36","first-page":"33","volume":"6","author":"Ibrahim H.","year":"2008","unstructured":"Ibrahim H.; Rahman A.F.A.; Pharmacokinetic parameters of valproic acid and carbamazepine from routinely collected data: Influence of patient characteristics. MJPS 2008,6(1),33-42","journal-title":"MJPS"},{"key":"ref=37","first-page":"80","volume":"64","author":"Krasniqi S.","year":"2010","unstructured":"Krasniqi S.; Neziri B.; Islami H.; Bauer S.; Carbamazepine and lamotrigine plasma concentrations in epileptic patients during optimising therapy. Med Arh 2010,64(2),80-83","journal-title":"Med Arh"},{"key":"ref=38","first-page":"125","volume":"34","author":"Budikayanti A.","year":"2017","unstructured":"Budikayanti A.; Khosama H.; Chaliana C.; Carbamazepine plasma level in temporal lobe epilepsy. Neurona 2017,34(3),125-131","journal-title":"Neurona"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/j.1600-0404.1996.tb00180.x","volume":"93","author":"Barcs G.","year":"1996","unstructured":"Barcs G.; Hal&#xE1;sz P.; Effectiveness and tolerance of clobazam in temporal lobe epilepsy. Acta Neurol Scand 1996,93(2-3),88-93","journal-title":"Acta Neurol Scand"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/S1059-1311(02)00287-X","volume":"12","author":"Shimizu H.","year":"2003","unstructured":"Shimizu H.; Kawasaki J.; Yuasa S.; Tarao Y.; Kumagai S.; Kanemoto K.; Use of clobazam for the treatment of refractory complex partial seizures. Seizure 2003,12(5),282-286","journal-title":"Seizure"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.yebeh.2011.02.015","volume":"21","author":"Meng H.","year":"2011","unstructured":"Meng H.; Guo G.; Ren J.; Zhou H.; Ge Y.; Guo Y.; Effects of ABCB1 polymorphisms on plasma carbamazepine concentrations and pharmacoresistance in Chinese patients with epilepsy. Epilepsy Behav 2011,21(1),27-30","journal-title":"Epilepsy Behav"}],"container-title":["Current Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886317666220414130526","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/203590\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1574886317666220414130526","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,27]],"date-time":"2023-03-27T00:42:36Z","timestamp":1679877756000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/203590\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1574886317666220414130526","relation":{},"ISSN":["1574-8863"],"issn-type":[{"value":"1574-8863","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-10-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-12-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}